Beta Drugs
Beta Drugs Performance
Day Range
- Low 1,170.00
- High 1,200.00
52 Week Range
- Low 600.00
- High 1,270.00
- Open Price1,180.00
- Previous Close1,167.90
- Volume2000
Start SIP in Beta Drugs
Start SIPBeta Drugs Investment Rating
-
Master Rating:
-
Beta Drugs has an operating revenue of Rs. 617.88 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 18% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 39% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator |
|---|
| Oper Rev Qtr Cr |
| Operating Expenses Qtr Cr |
| Operating Profit Qtr Cr |
| Depreciation Qtr Cr |
| Interest Qtr Cr |
| Tax Qtr Cr |
| Net Profit Qtr Cr |
Beta Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 15
- Bearish Moving Average
- ___
- 1
- 20 Day
- ₹1,135.45
- 50 Day
- ₹1,063.31
- 100 Day
- ₹984.87
- 200 Day
- ₹892.19
- 20 Day
- ₹1,140.42
- 50 Day
- ₹1,047.56
- 100 Day
- ₹961.68
- 200 Day
- ₹839.03
Beta Drugs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1,194.67 |
| Second Resistance | 1,212.33 |
| Third Resistance | 1,224.67 |
| RSI | 61.35 |
| MFI | 56.08 |
| MACD Single Line | 48.14 |
| MACD | 43.36 |
| Support | |
|---|---|
| First Resistance | 1,164.67 |
| Second Resistance | 1,152.33 |
| Third Resistance | 1,134.67 |
Beta Drugs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,000 | 180,000 | 90 |
| Week | 3,050 | 257,512 | 84.43 |
| 1 Month | 5,976 | 458,075 | 76.65 |
| 6 Month | 5,726 | 449,105 | 78.43 |
Beta Drugs Result Highlights
Beta Drugs Synopsis
NSE-Medical-Diversified
Beta Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 157.87 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2023. Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969.| Market Cap | 1,139 |
| Sales | 158 |
| Shares in Float | 0.32 |
| No of funds | 2 |
| Yield |
| Book Value | 11.67 |
| U/D Vol ratio | 1.1 |
| LTDebt / Equity | 4 |
| Alpha | 0.17 |
| Beta | 0.56 |
Beta Drugs
| Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
|---|---|---|---|---|
| Promoters | 66.73% | 66.73% | 66.73% | 66.71% |
| Foreign Portfolio Investors | 0.32% | 0.29% | 0.29% | 0.29% |
| Individual Investors | 22.37% | 22.24% | 22.52% | 22.6% |
| Others | 10.58% | 10.74% | 10.46% | 10.4% |
Beta Drugs Management
| Name | Designation |
|---|---|
| Mr. Rahul Batra | Chairman & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mr. Balwant Singh | Whole Time Director |
| Mrs. Seema Chopra | Whole Time Director |
| Mr. Ashutosh Shukla | Whole Time Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Rohit Parti | Independent Director |
Beta Drugs Forecast
Price Estimates
Beta Drugs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-11-07 | Quarterly Results & Others | To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of NSE and BSE. |
| 2023-05-08 | Audited Results | |
| 2022-10-27 | Quarterly Results | |
| 2022-04-27 | Audited Results | |
| 2021-10-25 | Quarterly Results |
Beta Drugs FAQs
What is Share Price of Beta Drugs ?
Beta Drugs share price is ₹1,177 As on 30 November, 2023 | 20:28
What is the Market Cap of Beta Drugs ?
The Market Cap of Beta Drugs is ₹1131.5 Cr As on 30 November, 2023 | 20:28
What is the P/E ratio of Beta Drugs ?
The P/E ratio of Beta Drugs is As on 30 November, 2023 | 20:28
What is the PB ratio of Beta Drugs ?
The PB ratio of Beta Drugs is 9.2 As on 30 November, 2023 | 20:28